Pipeline

October 14, 2019

Company	Drug/Device	Medical Condition	Status
Yumanity Therapeutics	YTX-7739	Parkinson’s disease	Phase 1 trial initiated enrolling 40 healthy subjects
Medivir AB	birinapant and radiation therapy	Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 1 trial initiated enrolling subjects with recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Debiopharm	Debio 1143, with Keytruda (pembrolizumab)	Pancreatic and colorectal cancer	Phase 1 trial initiated enrolling 46 subjects without other available therapeutic options
City of Hope	chimeric antigen receptor (CAR) T cells in combination with nivolumab (Opdivo) and ipilimumab (Yervoy)	glioblastoma	Phase 1 trial initiated
Hutchinson China MediTech Limited	HMPL-523	relapsed or refractory lymphoma	Phase 1/1b trial initiated doising subjects with relapsed or refractory lymphoma at sites in the U.S. and Europe
Nektar Therapeutics	NKTR-358 (LY3471851)	psoriasis	Phase 1b trial initiated enrolling 40 subjects with plaque psoriasis
Nektar Therapeutics	NKTR-358 (LY3471851)	atopic dermatitis	Phase 1b trial initiated enrolling 40 subjects with atopic dermatitis
DURECT Corporation	DUR-928	non-alcoholic steatohepatitis (NASH)	Phase 1b trial initiated enrolling 60 subjects with non-alcoholic steatohepatitis (NASH) with stage 1-3 fibrosis at multiple centers in the U.S.
AVROBIO, Inc.	investigational gene therapy	cystinosis	Phase 1/2 trial initiated four adult subjects and a potential follow-on cohort of two adults or adolescents at least 14 years of age who are currently being treated with cysteamine at UC San Diego
IDEAYA Biosciences, Inc.	cutaneous melanoma harboring a GNAQ or GNA11 (GNAQ/11) mutation	solid tumors	Phase 1/2 trial initiated
Minoryx Therapeutics	MIN-102	Friedreich’s Ataxia	Phase 2 trial initiated enrolling 39 subjects ages 12-60 with Friedreich’s Ataxia in four European countries
Oncologie	bavituximab in combination with KEYTRUDA (pembrolizumab)	gastroesophageal cancer	Phase 2 trial initiated enrolling 80 subjects with advanced gastric or gastroesophageal cancer in the U.S., UK, South Korea and Taiwan
Frequency Therapeutics	FX-322	Sensorineural Hearing Loss (SNHL)	Phase 2a trial initiated enrolling 96 adult subjects ages 18 to 65 with stable SNHL at 12 sites in the U.S.
DURECT Corporation	topical DUR-928	mild to moderate plaque psoriasis	Phase 2a trial enrolling 20 subjects in the U.S.
Graybug Vision, Inc.	GB-102	wet age-related macular degeneration (AMD)	Phase 2b trial initiated enrolling 160 subjects with wet AMD at more than 100 sites in the U.S.
iLiAD Biotechnologies, LLC	BPZE1	pertussis	Phase 2b trial initiated enrolling 300 healthy subjects
Dermira, Inc.	lebrikizumab	moderate to severe atopic dermatitis	Phase 3 trial initiated enrolling 800 adult and adolescent patients ages 12 and older with moderate-to-severe atopic dermatitis at 200 sites in the U.S., Europe and Asia
Galderma	nemolizumab	moderate to severe atopic dermatitis	Phase 3 trial initiated
Seattle Genetics, Inc.	tucatinib in combination with ado-trastuzumab emtansine (T-DM1, Kadcyla)	breast cancer	Phase 3 trial initiated enrolling up to 460 subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Beckman Coulter, Inc.	DxA 5000	pre-analytical sample quality detection	510 (k) clearance granted by the FDA
Frequency Therapeutics	FX-322	sensorineural hearing loss (SNHL)	Fast Track designation granted by the FDA
Novartis	Beovu (brolucizumab-dbll)	wet age-related macular degeneration (AMD)	Approval granted by the FDA
Clinuvel	Scenesse (afamelanotide)	erythropoietic protoporphyria (EPP)	Approval granted by the FDA
Gilead	Descovy	HIV pre-exposure prophylaxis	Approval granted by the FDA
AstraZeneca	FASENRA pen (benralizumab)	severe eosinophilic asthma	Approval granted by the FDA
Galderma	AKLIEF (trifarotene) Cream	acne	Approval granted by the FDA
Octapharma USA	WILATE	hemophilia A	Approval granted by the FDA